Medicare Enrolled
Dr. Neha Desouza, MD
Hematology & Oncology · Hayward, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Desouza from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Desouza?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Desouza
Dr. Neha Desouza is a hematology & oncology specialist in Hayward, CA, with 12 years of NPI registration. Based on federal Medicare data, Dr. Desouza performed 15,540 Medicare services across 1,043 unique beneficiaries.
Between the years covered by Open Payments, Dr. Desouza received a total of $11,790 from 76 pharmaceutical and/or device companies across 482 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Desouza is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice
▲ Top 25% volume in CA
$11,790 industry payments
Medicare Practice Summary
Medicare Utilization ↗15,540
Medicare services
Top 25% in CA for hematology & oncology
1,043
Unique beneficiaries
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,295 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 5,100 | $18 | $65 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
3,900 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,580 | $0 | $7 |
| MRI contrast dye injection (gadobutrol) | 1,350 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 660 | $1 | $94 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
452 | $8 | $17 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
416 | $8 | $32 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
296 | $14 | $82 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
296 | $83 | $366 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
268 | $30 | $142 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
247 | $157 | $467 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
177 | $142 | $653 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
143 | $49 | $264 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
122 | $107 | $360 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
70 | $20 | $87 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
60 | $66 | $290 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
60 | $1 | $9 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
49 | $1,704 | $6,748 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 49 | $288 | $1,133 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
46 | $78 | $256 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
35 | $172 | $930 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
31 | $157 | $533 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
30 | $318 | $1,370 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
29 | $72 | $198 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
23 | $104 | $280 |
| New patient office visit, complex (60-74 min) | 19 | $170 | $655 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
17 | $23 | $169 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $130 | $450 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.7% high complexity
84.0% medium
12.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,790
Total received (2018-2024)
Avg $1,684/year across 7 years
Top 29% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
76
Companies
482
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,217 (95.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$574 (4.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,836
2023
$2,442
2022
$1,962
2021
$1,366
2020
$929
2019
$925
2018
$330
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$367
Novartis Pharmaceuticals Corporation
$339
E.R. Squibb & Sons, L.L.C.
$322
Merck Sharp & Dohme LLC
$286
AstraZeneca Pharmaceuticals LP
$244
ABBVIE INC.
$241
Celgene Corporation
$241
PFIZER INC.
$158
Takeda Pharmaceuticals U.S.A., Inc.
$136
Regeneron Healthcare Solutions, Inc.
$108
SpringWorks Therapeutics, Inc.
$91
Gilead Sciences, Inc.
$90
GENZYME CORPORATION
$75
Coherus Biosciences Inc.
$68
GlaxoSmithKline, LLC.
$59
Pharmacosmos Therapeutics Inc.
$59
Genentech USA, Inc.
$58
Lilly USA, LLC
$56
Octapharma USA, Inc.
$55
Astellas Pharma US Inc
$51
Eisai Inc.
$49
Incyte Corporation
$47
Daiichi Sankyo Inc.
$47
Blueprint Medicines Corporation
$46
BeiGene USA, Inc.
$41
Azurity Pharmaceuticals, Inc.
$40
Exelixis Inc.
$37
JAZZ PHARMACEUTICALS INC.
$37
Deciphera Pharmaceuticals Inc.
$28
EMD Serono, Inc.
$28
ADC Therapeutics America, Inc.
$26
Aveo Pharmaceuticals, Inc.
$26
MorphoSys, US Inc.
$25
Myriad Genetic Laboratories, Inc.
$24
Ipsen Biopharmaceuticals, Inc
$24
TerSera Therapeutics LLC
$23
Agios Pharmaceuticals, Inc.
$22
Kyowa Kirin, Inc.
$22
Dexcom, Inc.
$21
Kite Pharma, Inc.
$21
PROGENICS PHARMACEUTICALS, INC.
$21
Legend Biotech USA Inc.
$20
Cardinal Health 414 LLC
$20
PUMA BIOTECHNOLOGY, INC.
$18
Rigel Pharmaceuticals, Inc.
$18
Top 3 companies account for 26.8% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,202
Janssen Biotech, Inc.
$886
AstraZeneca Pharmaceuticals LP
$865
Takeda Pharmaceuticals U.S.A., Inc.
$756
PFIZER INC.
$752
Novartis Pharmaceuticals Corporation
$639
Pharmacyclics LLC, An AbbVie Company
$496
Celgene Corporation
$481
Seagen Inc.
$436
Amgen Inc.
$381
Merck Sharp & Dohme LLC
$359
GENZYME CORPORATION
$294
ABBVIE INC.
$241
GlaxoSmithKline, LLC.
$237
Astellas Pharma US Inc
$229
Incyte Corporation
$205
Kite Pharma, Inc.
$177
Gilead Sciences, Inc.
$160
Eisai Inc.
$132
Pharmacyclics LLC, an AbbVie Company
$129
Puma Biotechnology, Inc.
$128
Lilly USA, LLC
$123
Daiichi Sankyo Inc.
$123
Myriad Genetic Laboratories, Inc.
$121
Genentech USA, Inc.
$114
Pharmacosmos Therapeutics Inc.
$112
Regeneron Healthcare Solutions, Inc.
$108
SpringWorks Therapeutics, Inc.
$91
Octapharma USA, Inc.
$85
Blueprint Medicines Corporation
$80
Merck Sharp & Dohme Corporation
$79
BeiGene USA, Inc.
$77
Bayer HealthCare Pharmaceuticals Inc.
$70
Coherus Biosciences Inc.
$68
ADC Therapeutics America, Inc.
$67
JAZZ PHARMACEUTICALS INC.
$66
EMD Serono, Inc.
$55
Acrotech Biopharma LLC
$54
Myovant Sciences Inc.
$53
EISAI INC.
$51
Ipsen Biopharmaceuticals, Inc
$50
Seattle Genetics, Inc.
$49
TerSera Therapeutics LLC
$45
PUMA BIOTECHNOLOGY, INC.
$41
Azurity Pharmaceuticals, Inc.
$40
Dexcom, Inc.
$37
Exelixis Inc.
$37
Dova Pharmaceuticals
$36
Rigel Pharmaceuticals, Inc.
$35
Clovis Oncology, Inc.
$35
SOBI, INC
$35
Foundation Medicine, Inc.
$33
Janssen Pharmaceuticals, Inc
$29
AVEO Pharmaceuticals, Inc.
$29
Deciphera Pharmaceuticals Inc.
$28
Aveo Pharmaceuticals, Inc.
$26
Sumitomo Pharma America, Inc.
$26
CTI BioPharma Corp.
$26
MorphoSys, US Inc.
$25
Global Blood Therapeutics, Inc.
$24
Alexion Pharmaceuticals, Inc.
$24
Stemline Therapeutics Inc.
$23
Taiho Oncology, Inc.
$23
Agios Pharmaceuticals, Inc.
$22
Kyowa Kirin, Inc.
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
PROGENICS PHARMACEUTICALS, INC.
$21
TAIHO ONCOLOGY, INC.
$20
Legend Biotech USA Inc.
$20
Cardinal Health 414 LLC
$20
G1 Therapeutics, Inc.
$20
Novocure Inc.
$18
AMAG Pharmaceuticals, Inc.
$18
Array BioPharma Inc.
$18
Novo Nordisk Inc
$17
West Therapeutics Development, LLC
$11
Top 3 companies account for 25.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Alecensa · BELEODAQ · BLENREP · BOSULIF · BRUKINSA · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · Crysvita · DARZALEX · Dexcom G6 Transmitter · Doptelet · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · FERAHEME · FOLOTYN · FOTIVDA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KIT FOR THE PREPARATION OF LYMPHOSEEK (TECHNETIUM TC 99M TILMANOCEPT) · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · NERLYNX · NINLARO · Nerlynx · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · ONIVYDE · OPDIVO · ORGOVYX · OXBRYTA · Onivyde · Optune · PADCEV · PEMAZYRE · PRECISETUMOR · PROLARIS · PROMACTA · PYLARIFY · PYRUKYND · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RYBELSUS · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · Stivarga · Subsys · TABRECTA · TAGRISSO · TASIGNA · TECVAYLI · TUKYSA · Tavalisse · Udenyca · Ultomiris · VERZENIO · VIVIMUSTA · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XTANDI · Xofigo · Xospata · Yescarta · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
189
Per 100K population
11.4
County median income
$126,240
Nearest hospital
ST ROSE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Desouza is a mixed practice specialist, with above-average Medicare volume (top 25% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Desouza experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Desouza performed 5,100 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Desouza receive payments from pharmaceutical companies?
Yes. Dr. Desouza received a total of $11,790 from 76 companies across 482 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Desouza's costs compare to other hematology & oncology specialists in Hayward?
Dr. Desouza's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Desouza) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Hayward
Browse hematology & oncology specialists in Hayward ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology